Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency, Madrid, Spain.
Psychother Psychosom. 2014;83(2):89-105. doi: 10.1159/000356498. Epub 2014 Jan 22.
There is a lack of scientific consensus about cancer comorbidity in people with central nervous system (CNS) disorders. This study assesses the co-occurrence of cancers in patients with CNS disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), autism spectrum disorders, Down's syndrome (DS), Huntington's disease (HD), multiple sclerosis (MS), Parkinson's disease (PD) and schizophrenia (SCZ).
Comprehensive search in PubMed/MEDLINE, Scopus and ISI Web of Knowledge of the literature published before March 2013. We identified 51 relevant articles from 2,229 discrete references, 50 of which contained data suitable for quantitative synthesis (577,013 participants). Pooled effect sizes (ES) were calculated using multiple random-effects meta-analyses. Sources of heterogeneity and uncertainty were explored by means of subgroup and sensitivity analyses, respectively.
The presence of CNS disorders was associated with a reduced co-occurrence of cancer (ES = 0.92; 95% confidence interval, CI: 0.87-0.98; I(2) = 94.5%). A consistently lower overall co-occurrence of cancer was detected in patients with neurodegenerative disorders (ES = 0.80; 95% CI: 0.75- 0.86; I(2) = 82.8%), and in those with AD (ES = 0.32; 95% CI: 0.22-0.46; I(2) = 0.0%), PD (ES = 0.83; 95% CI: 0.76-0.91; I(2) = 80.0%), MS (ES = 0.91; 95% CI: 0.87-0.95; I(2) = 30.3%) and HD (ES = 0.53; 95% CI: 0.42-0.67; I(2) = 56.4%). Patients with DS had a higher overall co-occurrence of cancer (ES = 1.46; 95% CI: 1.08-1.96; I(2) = 87.9%). No association was observed between cancer and ALS (ES = 0.97; 95% CI: 0.76-1.25; I(2) = 0.0%) or SCZ (ES = 0.98; 95% CI: 0.90-1.07; I(2) = 96.3%). Patients with PD, MS and SCZ showed (a) higher co-occurrence of some specific cancers (e.g. PD with melanoma, MS with brain cancers and SCZ with breast cancer), and (b) lower co-occurrence of other specific cancers (e.g. lung, prostate and colorectal cancers in PD; lung and prostate cancers in MS; and melanoma and prostate cancer in SCZ).
Increased and decreased co-occurrence of cancer in patients with CNS disorders represents an opportunity to discover biological and non-biological connections between these complex disorders.
中枢神经系统(CNS)疾病患者的癌症合并症尚未达成科学共识。本研究评估了 CNS 疾病患者癌症的共病情况,包括阿尔茨海默病(AD)、肌萎缩侧索硬化症(ALS)、自闭症谱系障碍、唐氏综合征(DS)、亨廷顿病(HD)、多发性硬化症(MS)、帕金森病(PD)和精神分裂症(SCZ)。
在 PubMed/MEDLINE、Scopus 和 ISI Web of Knowledge 中对截至 2013 年 3 月之前发表的文献进行全面检索。我们从 2229 个独立参考文献中确定了 51 篇相关文章,其中 50 篇包含适合定量综合分析的数据(577013 名参与者)。使用多个随机效应荟萃分析计算了合并效应大小(ES)。分别通过亚组和敏感性分析来探讨异质性和不确定性的来源。
CNS 疾病的存在与癌症共病率降低相关(ES = 0.92;95%置信区间,CI:0.87-0.98;I² = 94.5%)。在神经退行性疾病患者中(ES = 0.80;95%CI:0.75-0.86;I² = 82.8%)和 AD(ES = 0.32;95%CI:0.22-0.46;I² = 0.0%)、PD(ES = 0.83;95%CI:0.76-0.91;I² = 80.0%)、MS(ES = 0.91;95%CI:0.87-0.95;I² = 30.3%)和 HD(ES = 0.53;95%CI:0.42-0.67;I² = 56.4%)患者中,癌症的总体共病率较低。DS 患者的癌症总体共病率较高(ES = 1.46;95%CI:1.08-1.96;I² = 87.9%)。ALS(ES = 0.97;95%CI:0.76-1.25;I² = 0.0%)或 SCZ(ES = 0.98;95%CI:0.90-1.07;I² = 96.3%)与癌症之间无相关性。PD、MS 和 SCZ 患者的一些特定癌症的共病率更高(例如 PD 伴黑色素瘤、MS 伴脑癌和 SCZ 伴乳腺癌),而其他特定癌症的共病率更低(例如 PD 中的肺癌、前列腺癌和结直肠癌;MS 中的肺癌和前列腺癌;以及 SCZ 中的黑色素瘤和前列腺癌)。
CNS 疾病患者癌症的共病增加和减少代表了发现这些复杂疾病之间生物学和非生物学联系的机会。